Arbutus appoints Karen Sims as CMO, Christopher Naftzger as GC and CCO

Arbutus Biopharma Corp

Dr. Karen Sims promoted from VP Clinical Development to Chief Medical Officer, effective immediately.
Christopher Naftzger appointed General Counsel and Chief Compliance Officer; Dr. Elizabeth Howard remains advisor on patent litigation.
Naftzger granted inducement option for 500,000 common shares at July 10, 2023 closing price, vesting over 4 years.
Sims has 12+ years experience, previously at Bristol-Myers Squibb; Naftzger has 25+ years legal experience, most recently at Nabriva Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.